Recent

% | $
Quotes you view appear here for quick access.

Sanofi Message Board

scistats 378 posts  |  Last Activity: 22 hours ago Member since: Apr 5, 2009
  • Reply to

    Yes or No???

    by eastcoastcash Jan 23, 2016 11:11 AM
    scistats scistats Jan 25, 2016 9:05 AM Flag

    MACK could win a bidding war vs. JUNO?
    Now that's what I call a positive attitude.
    I am angry MACK didn't find CRISPR and beat everyone to the punch for PCYC.
    It is shameful!!!

    Sentiment: Strong Buy

  • scistats scistats Jan 25, 2016 8:57 AM Flag

    Strange target???

    "In Drosophilia, notch interaction with its cell-bound ligands (delta, serrate) establishes an intercellular signalling pathway that plays a key role in neural development. Homologues of the notch-ligands have also been identified in human, but precise interactions between these ligands and the human notch homologues remains to be determined. Mutations in NOTCH3 have been identified as the underlying cause of cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL). [provided by RefSeq, Jul 2008]"

    Neurogenic locus notch homolog protein 3 is a protein that in humans is encoded by the NOTCH3 gene.

    This gene encodes the third discovered human homologue of the Drosophilia melanogaster type I membrane protein notch. In Drosophilia, notch interaction with its cell-bound ligands (delta, serrate) establishes an intercellular signalling pathway that plays a key role in neural development. Homologues of the notch-ligands have also been identified in human, but precise interactions between these ligands and the human notch homologues remains to be determined.

    Sentiment: Strong Buy

  • scistats scistats Jan 25, 2016 8:54 AM Flag

    This is relevant to MACK:

    OncoMed Pharmaceuticals Inc. stock OMED, -40.07% plunged 37% in pre-market trade Monday, after an independent data safety monitoring board advised "of several findings regarding futility" of a Phase 2 clinical trial for a treatment of pancreatic cancer. The findings included a worsening of response rate and a strong trend toward a lack of benefit for overall survival. OncoMed said it is considering what to do next. Tarextumab is a product of a collaboration between OncoMed and GlaxoSmithKline GSK.

    Tarextumab (anti-Notch2/3, OMP-59R5) is a novel anti-cancer stem cell antibody that prevents signaling through both the Notch2 and Notch3 receptors. Tarextumab has been shown in preclinical models to inhibit cancer stem cell growth, and promote cell differentiation, as well as disrupt tumor angiogenesis by inhibiting vascular pericytes.

    Tarextumab is currently being studied in two randomized Phase 2 clinical trials. The ALPINE trial is assessing tarextumab with Abraxane plus gemcitabine in first-line advanced pancreatic cancer patients.

    In small cell lung cancer, tarextumab has demonstrated dose-dependent and biomarker driven activity. In pancreatic cancer, anti-tumor responses and prolonged survival rates versus standard of care were observed, particularly in patients whose tumors were identified as high in Notch3 gene expression using OncoMed’s biomarker assay.

    Sentiment: Strong Buy

  • Reply to

    Yes or No???

    by eastcoastcash Jan 23, 2016 11:11 AM
    scistats scistats Jan 25, 2016 8:45 AM Flag

    Inns, the CRISPR space IP is a legal disaster that is being battled out by the big boys and many many ants are on the sugar cube already.
    How the heck is MACK suppose to wade into the CRISPR mess and do anything but lose?
    MM-398 European approval and royalty will be the big 2016 news, and MM-141 is well positioned as an immune checkpoint player. The Merrimack strategy of dynamic, marker guided therapeutics make sense. No matter how bad everyone wants a cure-all, cancer is in fact many personalized (dynamic) diseases and has to be treated as such.

    Sentiment: Strong Buy

  • Reply to

    Yes or No???

    by eastcoastcash Jan 23, 2016 11:11 AM
    scistats scistats Jan 25, 2016 8:37 AM Flag

    Sure, go to the Merrimack website, right bar, menu, in development, MM-141, posters, MM-141 Preclinical Posters AACR-NCI-EORTC 2015 Istiratumab (MM-141), a bispecific antibody co-targeting IGF-1R and ErbB3, potentiates the activity of immune checkpoint inhibitors. Read the summary and data in results.

    Sentiment: Strong Buy

  • Reply to

    GERN is good.

    by scistats Jan 21, 2016 8:52 AM
    scistats scistats Jan 24, 2016 6:08 PM Flag

    Inns, believe it or not, people are allowed to make cases for technology, price points, and buyouts. Geron and Merrimack have close ties with Janssen and Shire, respectively, and both are excellent buyout candidates as trials progress. You are on both boards, so you obviously think there is great potential as well. Having said this, as we are on the GERN board, maybe we should limit the conversation here to GERN.

    Sentiment: Strong Buy

  • Reply to

    Yes or No???

    by eastcoastcash Jan 23, 2016 11:11 AM
    scistats scistats Jan 23, 2016 6:38 PM Flag

    MM-141 potentiates the anti-tumor activity of anti-PDL1. Genentech has atezolizumab an anti-PDL1.
    What do you think is going to happen to the PPS?

    Nano-liposomes with antibodies for putting chemo (and other select cargo) on target is just getting started with MM-302 and MM-310. MM-398 is already old school. Look out for MM-398-"gold" with antibodies and a combo load.

    I won't even mention the bone density patent for blocking mets of multiple cancer types, including breast and prostate cancer. Visions of sugar-plums might require an insulin shot.

    Sentiment: Strong Buy

  • Reply to

    i think mack has a lot of hidden value

    by chinaman.nyc2003 Jan 23, 2016 5:22 PM
    scistats scistats Jan 23, 2016 6:20 PM Flag

    8 cups fresh snow
    1 (14 oz) can sweetened condensed milk
    1 teaspoon vanilla extract
    dash of nutmeg
    mix, eat and enjoy!

    Sentiment: Strong Buy

  • MM-398 (Onivyde) regimen = MM-398 (liposome irinotecan) + 5-Fluorouracil + Leucovorin

    FOLFIRINOX:
    FOL ? folinic acid (leucovorin), a vitamin B derivative that modulates/potentiates/reduces the side effects of fluorouracil
    F ? fluorouracil (5#$%$), a pyrimidine analog and antimetabolite which incorporates into the DNA molecule and stops DNA synthesis
    IRIN ? irinotecan (Camptosar), a topoisomerase inhibitor, which prevents DNA from uncoiling and duplicating
    OX ? oxaliplatin (Eloxatin), a platinum-based antineoplastic agent, which inhibits DNA repair and/or DNA synthesis

    Can all three FOLFIRINOX active agents (FIRINOX) be packaged into a single liposome?
    Can Nab-paclitaxel + Gemcitabine be packaged into a single liposome?

    If so, the ideal treament would be:
    FIRINOX liposome front line.
    Then, (Nab-paclitaxel + Gemcitabine) liposome second line.

    Reference:
    Nab-paclitaxel + Gemcitabine after FOLFIRINOX failure (British Journal of Cancer 113, 989-995 (29 September 2015)

    Sentiment: Strong Buy

  • Reply to

    New Merrimack (MACK) Publication

    by scistats Jan 15, 2016 11:07 AM
    scistats scistats Jan 22, 2016 4:53 PM Flag

    Bump!

    Sentiment: Strong Buy

  • MM-141 potentiates the anti-tumor activity of anti-PD-L1. It at least doubles the number of complete remissions for tumors that are insulin-like growth factor 1 (IGF-1) receptor positive and HER3 (human epidermal growth factor receptor 3) positive or negative.

    Partner:
    Roche's MPDL3280A (an engineered anti-PDL1 antibody) + MM-141
    Roche’s investigational immunotherapy MPDL3280A doubled the likelihood of survival compared with chemotherapy in people with a specific type of lung cancer. Roche currently has three Phase II and six Phase III studies of MPDL3280A ongoing in various kinds of lung cancer.

    Sentiment: Strong Buy

  • scistats scistats Jan 22, 2016 2:53 PM Flag

    Absolutely, prostate cancer related bone pain usually requires pain meds and radiation. Fractures resulting in immobility cost quality of life and are a major health care cost burden.

    Before Hillary robs pharma to pay for her unsustainable healthcare plan, I hope she considers the cost savings a drug like Merrimack is developing will save. I bring this up because biotech is suffering already because she has made it clear that she plans to rob big pharma to subsidize her health insurance plan, even if it is unsustainable and this approach is entirely counterproductive and the opposite of what needs to be done.

    Sentiment: Strong Buy

  • scistats scistats Jan 22, 2016 2:06 PM Flag

    Looks like they want to block mets from forming at their first stop which is usually bone.
    Good call Merrimack!

    Sentiment: Strong Buy

  • scistats scistats Jan 22, 2016 2:02 PM Flag

    MM-398 sales crew is already on the street and the CRO's are handling the trials.
    Time to get on with new innovation like preventing bone mets.
    The patent suggests this IS their chosen "task" which is coming your way very soon my friend.

    Sentiment: Strong Buy

  • scistats scistats Jan 22, 2016 1:55 PM Flag

    By using a therapeutic that helps to maintain bone homeostasis, tumor formation at the bone may be prevented. If you prevent the metastases which many times occurs first at bones, you prevent cancer spread and subsequent death.

    Sentiment: Strong Buy

  • "Certain cancers, such as breast cancer and prostate cancer, have a propensity for metastasizing to bone where they disrupt bone homeostasis. Metastases of prostate cancer tend to be osteoblastic in nature while metastases of breast cancer are typically osteolytic. Metastatic breast cancers secrete several cytokines and growth factors that are known to affect osteoblast and osteoclast differentiation and function, including granulocyte macrophage colony stimulating factor (GMCSF), macrophage colony stimulating factor (MCSF), osteopontin (OPN), bone sialoprotein (BSP), parathyroid hormone related peptide (PTHrP), and interleukin-8 (IL-8)."

    Sentiment: Strong Buy

  • scistats scistats Jan 22, 2016 1:40 PM Flag

    Key concept: "zoledronic acid has antitumor activity" so "one of more molecules that specifically bind to CXC chemokine receptor 1 (CXCR1) and CXC chemokine receptor 2 (CXCR2)" may as well...

    Sentiment: Strong Buy

  • scistats scistats Jan 22, 2016 1:37 PM Flag

    FYI, prostate cancer.

    Urol Oncol. 2006 Jan-Feb;24(1):4-12.
    Rationale for zoledronic acid therapy in men with hormone-sensitive prostate cancer with or without bone metastasis. -Saad F, McKiernan J, Eastham J.

    Abstract

    Men with prostate cancer are at risk for bone loss and skeletal complications throughout the course of their disease. Bone loss is prevalent in many men with prostate cancer at initial diagnosis, and initiating androgen deprivation therapy results in accelerated bone resorption, leading to bone loss and an increased risk of fracture. These men are also at high risk for disease progression and bone metastases that can result in significant skeletal morbidity, including pathologic fracture, spinal cord compression, and debilitating bone pain requiring additional therapy. Excessive osteoclast activity plays a central role in the pathophysiology of bone disease at each stage of prostate cancer disease progression. Zoledronic acid, a highly potent inhibitor of osteoclast-mediated bone resorption, has increased bone mineral density in men receiving androgen deprivation therapy and is the only bisphosphonate that has shown statistically significant reductions in skeletal morbidity in patients with bone metastases from prostate cancer. Furthermore, preclinical evidence suggests that zoledronic acid has antitumor activity in prostate cancer models. Recently, a treatment algorithm was developed by the 3rd International Consultation on Prostate Cancer recommending the use of zoledronic acid for the prevention of skeletal complications in patients with bone metastases from prostate cancer, regardless of their hormone status, and for the prevention of treatment-induced bone loss in patients without evidence of bone metastases. According to this algorithm, zoledronic acid should be considered for the prevention of skeletal morbidity in patients with prostate cancer throughout their treatment continuum.

    Sentiment: Strong Buy

  • scistats scistats Jan 22, 2016 12:00 PM Flag

    You have to wonder how far along MACK is with their bone loss prevention program.
    Exciting!

    Sentiment: Strong Buy

  • COMPOSITIONS AND METHODS FOR TREATING OSTEOLYTIC BONE DISORDERS
    United States Patent Application 20160017046
    Publication Date: 01/21/2016

    "FIELD OF THE INVENTION
    The present invention relates to compositions and methods useful for treating osteolytic bone disorders. More specifically, the invention relates to compositions comprising one of more molecules that specifically bind to CXC chemokine receptor 1 (CXCR1) and CXC chemokine receptor 2 (CXCR2) and methods for treating and improving the symptoms of pathologic bone loss in a subject by administering to the subject a therapeutically effective amount of such compositions."

    Sentiment: Strong Buy

SNY
38.98+0.61(+1.59%)Feb 12 4:01 PMEST